According to the research report titled ‘Global Transcatheter Tricuspid Valve Intervention (TTVI) Market - Analysis By Intervention Type (TVr, TVR), Disease Type (TR, TS), End User, By Region, By Country (2021 Edition): Market Insights, Pipeline, COVID-19 Implications, Competition and Forecast (2021-2030)’, available with MarketStudyReport, global transcatheter tricuspid valve intervention (TTVI) market is speculated to be worth USD 10.17 billion by the end of the forecast period 2021-2030.

As per report findings, growing ageing population and their susceptibility to tricuspid valve diseases, alongside rising advancements in technology and upcoming approvals of new medical devices across various countries are primarily driving global transcatheter tricuspid valve intervention (TTVI) market growth.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4331005/  

Additionally, increasing preference for these devices for treatment among practitioners, and growing popularity of minimally invasive surgeries over open heart surgeries are likely to propel industry development in the upcoming years.

Notably, the COVID-19 pandemic wreaked havoc over the global medical industry and shifted the focus as well as resources from various sectors including cardiovascular (heart) care to coronavirus management. The epidemic also disrupted the progress of clinical & confirmatory trials, regulatory clearances of tricuspid valve repair & replacement devices, and pipeline milestones due to the widespread lockdowns, travel bans, and social distancing norms. These factors have fundamentally affected the potential progress of worldwide transcatheter tricuspid valve intervention (TTVI) industry over the upcoming years.

Based in intervention type, the industry is divided into tricuspid valve replacement, and tricuspid valve repair. Different disease types are tricuspid stenosis, and tricuspid regurgitation. While the end-user scope includes ambulatory surgical centers, hospitals, and others.

On the regional front, the research literature classifies the industry into North America (United States, Canada), Europe (Germany, France, United Kingdom, Italy), Asia Pacific (Japan, China, India, Australia).

Considering the competitive landscape, companies such as Venus MedTech (HangZhou) Inc., CryoLife Inc., LivaNova plc, Medtronic plc, Abbott Laboratories, HuiHe Healthcare, 4Tech Inc., Jenscare Biotechnology Co., NaviGate Cardiac Structures Inc., and Edwards Lifesciences prominently influence global transcatheter tricuspid valve intervention (TTVI) industry trends.